Bio-Rad offers a wide assortment of empty and prepacked columns and resins for analytical and preparative chromatography applications — use with Bio-Rad’s chromatography systems or any chromatography system.
Hercules, CA — March 2, 2015 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of new PrimePCR Droplet Digital PCR (ddPCR™) Assays. This release expands Bio-Rad’s offering of predesigned validated copy number assays to a total of 658 targets, 57 of which are centromeric reference assays. The mutation detection assay offering now covers 209 mutations, of which 184 have short amplicon assays available for use with fragmented and challenging samples. This expansion also introduces assays for transcriptome-wide gene expression analysis of human, mouse, and rat genomes. In total, Bio-Rad now offers more than 120,000 PrimePCR Assays for use with Droplet Digital PCR.
Droplet Digital PCR (ddPCR™) is Bio-Rad's unique digital PCR technology. With unrivaled precision, ddPCR provides absolute quantification of target DNA or RNA molecules without the use of standard curves. ddPCR addresses the lack of scalable and practical technologies for digital PCR implementation. The QX200™ ddPCR System puts this powerful technology in your hands, ready to unveil new worlds of research at previously unattainable levels.
Download the Droplet Digital PCR Applications Guide for in-depth information about setting up experiments.
Hercules, CA — January 12, 2015 — Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today announced the launch of the ddPCR™ KRAS Screening Multiplex Kit, the latest offering in the company’s Droplet Digital™ PCR line of predesigned, fully wet-lab validated assays. The ddPCR KRAS Screening Multiplex Kit offers improved sensitivity and simultaneous detection of the seven most common KRAS mutations in a single ddPCR experiment.
KRAS mutations are found in 90% of pancreatic cancer cases and 30% of colorectal cancer cases, making it a gene of great interest to cancer researchers. The Multiplex Kit is able to detect and quantify extremely low levels (down to 0.2%) of KRAS mutant DNA in a single assay. Cancer samples are often available in limited quantities. Using the Multiplex Kit, researchers can derive results from low amounts of starting material.
Parāda 1 - 4 no 22 jaunumiem